glp-1 and lupus Receptor Agonists Reduce Cardiovascular Kidney Risks in Patients with Type 2 Diabetes: Study GLP-1 and Inflammation: How These

Potential Health Improvements: Weight loss achieved with GLP-1 Agonist can lead to improvements in weight-related health conditions like blood pressure, blood sugar control, and cholesterol levels

9.9% of patients in the tirzepatide group experienced adjudicated CV death or worsening heart failure events compared with 15.3% in the placebo group (HR, 0.62

The PKPD model recapitulates longitudinal weight loss data from three randomized, doubleblind, controlled trials of subcutaneous semaglutide

Gastrointestinal intolerance, particularly nausea and vomiting, may affect adherence despite their tendency to diminish over time (Liu et al., 2022)

Biological basis of depression in adults with diabetes